Zoetis/$ZTS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Ticker
$ZTS
Sector
Primary listing
NYSE
Employees
13,800
Headquarters
Website
Zoetis Metrics
BasicAdvanced
$52B
19.99
$5.94
0.96
$2.00
1.69%
Price and volume
Market cap
$52B
Beta
0.96
52-week high
$177.40
52-week low
$115.25
Average daily volume
4.9M
Dividend rate
$2.00
Financial strength
Current ratio
3.643
Quick ratio
2.006
Long term debt to equity
135.05
Total debt to equity
135.05
Dividend payout ratio (TTM)
32.55%
Interest coverage (TTM)
16.50%
Profitability
EBITDA (TTM)
3,988
Gross margin (TTM)
71.72%
Net profit margin (TTM)
28.21%
Operating margin (TTM)
37.92%
Effective tax rate (TTM)
20.41%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
15.08%
Return on equity (TTM)
49.87%
Valuation
Price to earnings (TTM)
19.986
Price to revenue (TTM)
5.638
Price to book
9.7
Price to tangible book (TTM)
32.86
Price to free cash flow (TTM)
23.653
Free cash flow yield (TTM)
4.23%
Free cash flow per share (TTM)
5.016
Dividend yield (TTM)
1.69%
Forward dividend yield
1.69%
Growth
Revenue change (TTM)
2.68%
Earnings per share change (TTM)
11.64%
3-year revenue growth (CAGR)
5.48%
10-year revenue growth (CAGR)
6.92%
3-year earnings per share growth (CAGR)
10.69%
10-year earnings per share growth (CAGR)
21.03%
3-year dividend per share growth (CAGR)
16.40%
10-year dividend per share growth (CAGR)
19.66%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Zoetis News
AllArticlesVideos
Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats
Business Wire19 hours ago
Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast
Business Wire4 days ago
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zoetis stock?
Zoetis (ZTS) has a market cap of $52B as of December 06, 2025.
What is the P/E ratio for Zoetis stock?
The price to earnings (P/E) ratio for Zoetis (ZTS) stock is 19.99 as of December 06, 2025.
Does Zoetis stock pay dividends?
Yes, the Zoetis (ZTS) stock pays dividends to shareholders. As of December 06, 2025, the dividend rate is $2 and the yield is 1.69%. Zoetis has a payout ratio of 32.55% on a trailing twelve-month basis.
When is the next Zoetis dividend payment date?
The next Zoetis (ZTS) dividend payment date is unconfirmed.
What is the beta indicator for Zoetis?
Zoetis (ZTS) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.